735 POSTER Randomized comparison of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer

首页> 外文期刊>European Journal of Cancer Supplements >735 POSTER Randomized comparison of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer

【24h】

735 POSTER Randomized comparison of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer

机译：735海报随机比较卡培他滨加奥沙利铂（CapOx），卡培他滨加吉西他滨（CapGem）与吉西他滨加奥沙利铂（GemOx）在晚期胰腺癌中的随机比较

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. [J] . Boeck S, Hoehler T, Seipelt G, Annals of oncology: official journal of the European Society for Medical Oncology . 2008,第2期

机译：卡培他滨加奥沙利铂（CapOx）与卡培他滨加吉西他滨（CapGem）与吉西他滨加奥沙利铂（mGemOx）：一项多中心随机II期晚期胰腺癌试验的最终结果。
2. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer [J] . S. Boeck1 T. Hoehler2 G. Seipelt3 R. Mahlberg4 A. Wein5 A. Hochhaus6 H.-P. Boeck7 B. Schmid8 E. Kettner9 M. Stauch10 F. Lordick11 Y. Ko12 M. Geissler13 K. Schoppmeyer14 G. Kojouharoff15 A. Golf16 S. Neugebauer17 and V. Heinemann1* Annals of Oncology . 2008,第2期

机译：卡培他滨加奥沙利铂（CapOx）与卡培他滨加吉西他滨（CapGem）与吉西他滨加奥沙利铂（mGemOx）：一项多中心随机II期晚期胰腺癌试验的最终结果
3. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial [J] . Kim S. T., Kang J. H., Lee J., Annals of oncology: official journal of the European Society for Medical Oncology . 2019,第5期

机译：Capecitabine Plus oxaliplatin与Gemcitabine Plus oxaliplatin作为高级胆道癌症的一线治疗：多中心，开放标签，随机，第三阶段，非流动性试验
4. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104) [O] . Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, -1

机译：吉西他滨联合厄洛替尼接着卡培他滨卡培他滨与加Erlotinib随后吉西他滨在晚期胰腺癌：在arbeitsgemeinschaft Internistische Onkologie的随机III期试验的最终结果（aIO-pK0104）
5. First Line Treatment for Advanced Gastroesophageal Cancer: Capecitabine Plus Oxaliplatin (CAPOX) versus Epirubicin, Oxaliplatin Plus Capecitabine (EOX) [O] . Kayal S 2017

机译：晚期胃食管癌的第一线治疗：Capecitabine Plus Oxaliplatin（Capox）对象，Oxaliplatin加上卡押沙明（Eox）

735 POSTER Randomized comparison of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer

著录项

相似文献

相关主题

期刊订阅